WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2005014008) TREATMENT OF DISORDERS ASSOCIATED WITH NATURAL KILLER T CELLS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/014008    International Application No.:    PCT/US2004/022913
Publication Date: 17.02.2005 International Filing Date: 16.07.2004
IPC:
A61K 31/7032 (2006.01)
Applicants: THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; 6011 Executive Boulevard, Suite 325, Rockville, MD 20852 (US) (For All Designated States Except US).
ORTALDO, John [US/US]; (US) (For US Only).
WILTROUT, Robert [US/US]; (US) (For US Only)
Inventors: ORTALDO, John; (US).
WILTROUT, Robert; (US)
Agent: PATTON, Stephana, E.; Edwards & Angell, LLP, 101 Federal Street, P.O. Box 55874, Boston, MA 02205-5874 (US)
Priority Data:
60/488,339 17.07.2003 US
Title (EN) TREATMENT OF DISORDERS ASSOCIATED WITH NATURAL KILLER T CELLS
(FR) PROCEDES ET COMPOSITIONS DE TRAITEMENT DE MALADIE ET DE TROUBLES ASSOCIES A DES LYMPHOCYTES TNK
Abstract: front page image
(EN)The invention relates to methods and compositions useful in the treatment of autoimmune disorders or diseases as well as disorders or diseases having an autoimmune component such as AIDS cancer and organ rejection. Preferred methods and compositions of the invention comprise use of a Beta Galactosyl Ceramide compound to treat a mammal suffering from or susceptible to such disorders. Methods and compositions of the invention can reduce NKT cells effectively in vivo in the substantial absence of undesired bystander events (cellular activation, cytokine production, systemic inflammation, etc). Methods and compositions of the invention can also reduce tumor size or ability to metastasize.
(FR)L'invention concerne des procédés et des compositions utiles dans le traitement de troubles ou de maladies auto-immunes ainsi que de troubles ou de maladies possédant une composante auto-immunitaire, notamment le sida. Des procédés et des compositions préférés de l'invention utilisent un composé de bêta galactosyl céramide afin de traiter un mammifère souffrant ou étant susceptible de souffrir de tels troubles. Ces procédés et ces compositions peuvent réduire les lymphocytes TNK de manière efficace <i>in vivo</i> en l'absence substantielle d'événements tiers non désirés (activation cellulaire, production de cytokine, inflammation systémique, etc.). Ces procédés et ces compositions peuvent également réduire la taille de tumeurs ou la capacité à métastaser.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)